Alkermes Corporate Responsibility

Alkermes underscores its commitment to central nervous system (CNS) disorders, such as schizophrenia, depression and addiction, by supporting educational, healthcare-related, and public policy events through sponsorships, charitable and educational grants programs, as well as through investigator initiated trials. In addition, Alkermes fosters and maintains collaborative relationships with health-related and public policy organizations through corporate memberships.

Dedicated to Continuous Improvement

“Our success as a global biopharmaceutical company is predicated on our ability to ask the right questions and to energetically seek answers. How can a new medicine be best designed? How can patient outcomes be improved? How can we structure our company to best serve patients, employees and communities? Our culture of inquiry and collaborative problem-solving strengthens our business and underpins how we approach corporate responsibility. We are dedicated to continuous improvement in both our solutions for patients and our performance as a responsible corporate citizen.”

- Richard F. Pops
- Chief Executive Officer

For more information about Alkermes Corporate Responsibility, please download the Alkermes 2017 Corporate Responsibility Review.